Interventional technology developer Boston Scientific has completed its acquisition of C. R. Bard's electrophysiology (EP) division. Terms of the deal were not disclosed.
Boston Scientific said the deal was a bid to serve the rapidly expanding global EP market, and that it would broaden its portfolio of EP products, including devices used for cardiac catheter ablations to treat patients with cardiac arrhythmias.
In addition to new expertise in capital equipment sales and service, the deal will help Boston Scientific accelerate the launch of key technologies, including the IntellaTip MiFi XP ablation catheter and Rhythmia mapping system, the firm said.
